Adherence to Oral Anticancer Medications Among Women With Breast Cancer in Africa: A Scoping Review

Overview

Journal JCO Glob Oncol

Specialty Oncology

Date 2023 Jan 23

PMID 36689700

Authors

Deborah O Onwusah

Elizabeth B Ojewole

Moses J Chimbari

Affiliations

Soon will be listed here.

Abstract

Purpose: Oral anticancer medications (OAMs) improve treatment outcomes and survival in women with breast cancer (BC). However, adherence to OAM therapy remains suboptimal. This scoping review provides evidence of adherence to OAMs among African women with BC.

Methods: We searched four databases and gray literature, using guidance from the Joanna Briggs Institute. Thirteen studies on adherence rates, determinants, and interventions were included. NVivo 12 software was used to perform thematic analysis of the included studies. The determinants (barriers and facilitators) associated with adherence were analyzed according to the five dimensions of the WHO multidimensional adherence model.

Results: Most studies (n = 11, 85%) focused on endocrine medication. Depending on the definition, measurements, and assessment period, the nonadherence rates ranged from 4.3% to 65.4% for endocrine medications, 80.9% for cytotoxic chemotherapies, and 32.7% for combined medications. The significant barriers associated with adherence include Islamic religion, concurrent comorbidities, mastectomy, anastrozole treatment, side effects, unawareness of treatment insurance coverage, and seeking treatment from traditional healers. Thorough therapeutic communication regarding treatment, neoadjuvant chemotherapy, and adequate social support significantly facilitate adherence. A randomized controlled trial of breast nursing interventions reported improved patient adherence.

Conclusion: The evidence mapped from studies that evaluated OAM adherence in women with BC indicates that nonadherence to OAMs is common. Applying context-specific standardized measures to assess adherence and facilitators or strategies targeting the identified barriers can optimize adherence and treatment outcomes. Effective interventions to improve adherence are limited. Therefore, further empirical and interventional studies in Africa are required to enhance the evidence.

Citing Articles

Adherence, clinical benefits, and adverse effects of endocrine therapies among women with nonmetastatic breast cancer in developing countries: A systematic review and meta-analysis.

Elshafie S, Trivedi R, Villa-Zapata L, Tackett R, Zaghloul I, Young H Cancer. 2024; 131(1):e35550.

PMID: 39235037 PMC: 11694169. DOI: 10.1002/cncr.35550.

Association between culture and the preference for, and perceptions of, 11 routes of medicine administration: A survey in 21 countries and regions.

Murdan S, Wei L, van Riet-Nales D, Gurmu A, Usifoh S, Taerel A Explor Res Clin Soc Pharm. 2023; 12:100378.

PMID: 38094713 PMC: 10716026. DOI: 10.1016/j.rcsop.2023.100378.

Barriers and Facilitators of Adherence to Oral Anticancer Medications Among Women with Breast Cancer: A Qualitative Study.

Onwusah D, Ojewole E, Manyangadze T, Chimbari M Patient Prefer Adherence. 2023; 17:2821-2839.

PMID: 37953981 PMC: 10637192. DOI: 10.2147/PPA.S416843.

References

Partridge A, Archer L, Kornblith A, Gralow J, Grenier D, Perez E . Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol. 2010; 28(14):2418-22. PMC: 2881723. DOI: 10.1200/JCO.2009.26.4671. View

Eek D, Krohe M, Mazar I, Horsfield A, Pompilus F, Friebe R . Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016; 10:1609-21. PMC: 5003561. DOI: 10.2147/PPA.S106629. View

Bramer W, Giustini D, de Jonge G, Holland L, Bekhuis T . De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016; 104(3):240-3. PMC: 4915647. DOI: 10.3163/1536-5050.104.3.014. View

Degu A, Kebede K . Drug-related problems and its associated factors among breast cancer patients at the University of Gondar Comprehensive Specialized Hospital, Ethiopia: A hospital-based retrospective cross-sectional study. J Oncol Pharm Pract. 2020; 27(1):88-98. DOI: 10.1177/1078155220914710. View

Tang M, Schaffer A, Kiely B, Daniels B, Simes R, Lee C . Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016). Br J Cancer. 2019; 121(11):904-911. PMC: 6889396. DOI: 10.1038/s41416-019-0612-5. View

Adisa A, Lawal O, Adesunkanmi A . Paradox of wellness and nonadherence among Nigerian women on breast cancer chemotherapy. J Cancer Res Ther. 2008; 4(3):107-10. DOI: 10.4103/0973-1482.42640. View

Zeeneldin A, Gaber A, Taha F . Does fasting during Ramadan trigger non-adherence to oral hormonal therapy in breast cancer patients?. J Egypt Natl Canc Inst. 2012; 24(3):133-7. DOI: 10.1016/j.jnci.2012.06.003. View

Mathes T, Antoine S, Pieper D, Eikermann M . Adherence enhancing interventions for oral anticancer agents: a systematic review. Cancer Treat Rev. 2013; 40(1):102-8. DOI: 10.1016/j.ctrv.2013.07.004. View

Cahir C, Barron T, Sharp L, Bennett K . Can demographic, clinical and treatment-related factors available at hormonal therapy initiation predict non-persistence in women with stage I-III breast cancer?. Cancer Causes Control. 2017; 28(3):215-225. DOI: 10.1007/s10552-017-0851-9. View

10.

McCowan C, Wang S, Thompson A, Makubate B, Petrie D . The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer. 2013; 109(5):1172-80. PMC: 3778308. DOI: 10.1038/bjc.2013.464. View

11.

Masoud V, Pages G . Targeted therapies in breast cancer: New challenges to fight against resistance. World J Clin Oncol. 2017; 8(2):120-134. PMC: 5385433. DOI: 10.5306/wjco.v8.i2.120. View

12.

Benn C, Ramdas Y, Smit T, Shaw V, Rapoport B . Analysis of primary endocrine therapy in patients older than 70 years with breast cancer rejecting surgery from a single unit in South Africa including COVID-19 issues. J Geriatr Oncol. 2021; 12(7):1118-1121. PMC: 7923858. DOI: 10.1016/j.jgo.2021.02.024. View

13.

Clancy C, Lynch J, OConnor P, Dowling M . Breast cancer patients' experiences of adherence and persistence to oral endocrine therapy: A qualitative evidence synthesis. Eur J Oncol Nurs. 2020; 44:101706. DOI: 10.1016/j.ejon.2019.101706. View

14.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

15.

Gao P, You L, Wu D, Shi A, Miao Q, Rana U . Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement. Patient Prefer Adherence. 2018; 12:887-897. PMC: 5973402. DOI: 10.2147/PPA.S167004. View

16.

Reibold C, Tariku W, Eber-Schulz P, Getachew S, Addisie A, Unverzagt S . Adherence to Newly Implemented Tamoxifen Therapy for Breast Cancer Patients in Rural Western Ethiopia. Breast Care (Basel). 2021; 16(5):484-490. PMC: 8543345. DOI: 10.1159/000512840. View

17.

Schneider S, Hess K, Gosselin T . Interventions to promote adherence with oral agents. Semin Oncol Nurs. 2011; 27(2):133-41. PMC: 3653175. DOI: 10.1016/j.soncn.2011.02.005. View

18.

Hall A, Paul C, Bryant J, Lynagh M, Rowlings P, Enjeti A . To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients. Crit Rev Oncol Hematol. 2015; 97:247-62. DOI: 10.1016/j.critrevonc.2015.08.025. View

19.

McGowan J, Straus S, Moher D, Langlois E, OBrien K, Horsley T . Reporting scoping reviews-PRISMA ScR extension. J Clin Epidemiol. 2020; 123:177-179. DOI: 10.1016/j.jclinepi.2020.03.016. View

20.

Lehmann A, Aslani P, Ahmed R, Celio J, Gauchet A, Bedouch P . Assessing medication adherence: options to consider. Int J Clin Pharm. 2013; 36(1):55-69. DOI: 10.1007/s11096-013-9865-x. View